DOCSLIB.ORG

Public Assessment Reports for These Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Public Assessment Reports for These Products 25 July 2013 EMA/CHMP/207780/2013 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Vipidia International non-proprietary name: alogliptin Procedure No. EMEA/H/C/002182/0000 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier ...................................................................................... 5 1.2. Manufacturers ...................................................................................................... 6 1.3. Steps taken for the assessment of the product ......................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction......................................................................................................... 7 2.2. Quality aspects .................................................................................................... 8 2.2.1. Introduction ...................................................................................................... 8 2.2.2. Active Substance Alogliptin Benzoate ................................................................... 8 2.2.3. Finished Medicinal Product ................................................................................ 10 2.2.4. Discussion on chemical, pharmaceutical and biological aspects .............................. 12 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 12 2.2.6. Recommendation for future quality development ................................................. 13 2.3. Non-clinical aspects ............................................................................................ 13 2.3.1. Introduction .................................................................................................... 13 2.3.2. Pharmacology ................................................................................................. 13 2.3.3. Pharmacokinetics............................................................................................. 16 2.3.4. Toxicology ...................................................................................................... 21 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 25 2.3.6. Discussion on non-clinical aspects...................................................................... 27 2.3.7. Conclusion on the non-clinical aspects ................................................................ 30 2.4. Clinical aspects .................................................................................................. 30 2.4.1. Introduction .................................................................................................... 30 2.4.2. Pharmacokinetics............................................................................................. 32 2.4.3. Pharmacodynamics .......................................................................................... 35 2.4.4. Discussion on clinical pharmacology ................................................................... 36 2.4.5. Conclusions on clinical pharmacology ................................................................. 38 2.5. Clinical efficacy .................................................................................................. 38 2.5.1. Dose response study ........................................................................................ 38 2.5.2. Main studies ................................................................................................... 39 2.5.3. Discussion on clinical efficacy ............................................................................ 70 2.5.4. Conclusions on the clinical efficacy ..................................................................... 73 2.6. Clinical safety .................................................................................................... 73 2.6.1. Discussion on clinical safety .............................................................................. 84 2.6.2. Conclusions on the clinical safety ....................................................................... 87 2.7. Pharmacovigilance .............................................................................................. 87 2.8. Risk Management Plan ........................................................................................ 87 2.9. User consultation ............................................................................................... 90 3. Benefit-Risk Balance.............................................................................. 90 4. Recommendations ................................................................................. 95 CHMP assessment report EMA/CHMP/207780/2013 Page 2/96 List of abbreviations ADME absorption, distribution, metabolism, and excretion ADR adverse drug reaction Ae total amount of drug excreted A/G albumin/globulin ALB albumin ALP alkaline phosphatase ALT alanine aminotransferase ANCOVA analysis of covariance ANOVA analysis of variance API Active Pharmaceutical Ingredient ADR adverse drug reactions AR Assessment Report ASM Active Substance Manufacturer AST aspartate aminotransferase AUC area under the plasma concentration-time curve AUC(0-inf) area under the plasma concentration-time curve from time 0 to time infinity BA bioavailability BID twice per day %CV percent coefficient of variation Caco-2 human colonic adenocarcinoma CHO Chinese hamster ovary CI confidence interval CK creatine kinase Cl chloride CL clearance CLr renal clearance Cmax maximum observed plasma concentration CNS central nervous system Cr serum creatinine CrCl creatinine clearance CRP C-reactive protein CYP cytochrome P-450 DASH DASH DPP-4 activity and/or structure homologues DPP-2,-4… dipeptidyl peptidase-2, 4, … E2 estradiol EC50 half-maximal effective concentration ECG electrocardiogram FDC fixed-dose combination GC Gas Chromatography GD Gestation Day GFR glomerular filtration rate GGT γ-glutamyl transferase GHb glycosylated hemoglobin GI gastrointestinal GIP glucose-dependent insulinotropic peptide GLP Good Laboratory Practice GLP-1 glucagon-like peptide-1 Glut2 glucose transporter 2 GMP Good Manufacturing Practice HbA1c glycosylated hemoglobin HCl Hydrochloric acid HCT hematocrit HDL high-density lipoprotein HDL-C high-density lipoprotein cholesterol HGB haemoglobin HPLC high-performance liquid chromatography ICH International Conference on Harmonisation IC50 50% inhibitory concentration IDL intermediate-density lipoprotein IP intraperitoneal CHMP assessment report EMA/CHMP/207780/2013 Page 3/96 IPC In-process control IR Infrared IR immunoreactivity ITT intent to treat IV intravenously ka absorption constant KF Karl Fischer LD Lactation Day LDH lactate dehydrogenase LDL low-density lipoprotein LDL-C Low-density lipoprotein cholesterol LDPE Low Density Polyethylene LH luteinizing hormone LS least squares M-I, M-II, … metabolite I, I … LYM lymphocytes MAA Marketing Authorisation Application MET metformin MON monocytes MS Mass Spectrometry MTD maximum tolerated dose N/A not applicable ND Not detected NOAEL no-observed-adverse-effect level NT Not tested OGTT oral glucose tolerance test OAT organic anion transporters PCTFE Polychlorotrifluoroethylene pdx-1 insulin promoter transcription factor PE Polyethylene Ph.Eur. European Pharmacopoeia PIP Paediatric Investigation Plan PK Pharmacokinetic PO by mouth PPARγ peroxisome proliferator–activated receptorγ Ppg postprandial glucose PSUR Periodic Safety Update Report PT prothrombin time PVC Polyvinylchloride QTc QT interval corrected for heart rate RBC red blood cell RET reticulocytes RH Relative Humidity RV residual variability SAE serious adverse event SC subcutaneous SCr serum creatinine %SEM standard error of the parameter estimate divided by the parameter estimate 100% STZ streptozotocin SU sulfonylurea T1/2 or T1/2, z terminal elimination half-life T2DM type 2 diabetes mellitus TFA triflouroacetate salt TG triglycerides TLC Thin Layer Chromatography Tmax time to reach Cmax TS tosylate salt TZD thiazolidinedione ULN upper limit of normal UN urea nitrogen USP United States Pharmacopoeia UV Ultraviolet WBC white blood cells CHMP assessment report EMA/CHMP/207780/2013 Page 4/96 1. Background information on the procedure 1.1. Submission of the dossier The applicant Takeda Global Research and Development Centre (Europe) Limited submitted on 2 May 2012 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Vipidia, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004 . The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 20 October 2011. During the procedure the applicant has changed to Takeda Pharma A/S. The applicant applied for the following indication: Vipidia is indicated to improve glycaemic control in adult patients (≥ 18 years old) with type 2 diabetes mellitus: in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. in
Load more

Recommended publications
  • Review of Market for Octane Enhancers
    May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado NREL Technical Monitor: K. Ibsen Prepared under Subcontract No. TXE-0-29113-01 National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 NOTICE This report was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or any agency thereof. Available electronically at http://www.doe.gov/bridge Available for a processing fee to U.S.
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017
    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
    [Show full text]
  • Organocatalytic Asymmetric N-Sulfonyl Amide C-N Bond Activation to Access Axially Chiral Biaryl Amino Acids
    ARTICLE https://doi.org/10.1038/s41467-020-14799-8 OPEN Organocatalytic asymmetric N-sulfonyl amide C-N bond activation to access axially chiral biaryl amino acids Guanjie Wang1, Qianqian Shi2, Wanyao Hu1, Tao Chen1, Yingying Guo1, Zhouli Hu1, Minghua Gong1, ✉ ✉ ✉ Jingcheng Guo1, Donghui Wei 2 , Zhenqian Fu 1,3 & Wei Huang1,3 1234567890():,; Amides are among the most fundamental functional groups and essential structural units, widely used in chemistry, biochemistry and material science. Amide synthesis and trans- formations is a topic of continuous interest in organic chemistry. However, direct catalytic asymmetric activation of amide C-N bonds still remains a long-standing challenge due to high stability of amide linkages. Herein, we describe an organocatalytic asymmetric amide C-N bonds cleavage of N-sulfonyl biaryl lactams under mild conditions, developing a general and practical method for atroposelective construction of axially chiral biaryl amino acids. A structurally diverse set of axially chiral biaryl amino acids are obtained in high yields with excellent enantioselectivities. Moreover, a variety of axially chiral unsymmetrical biaryl organocatalysts are efficiently constructed from the resulting axially chiral biaryl amino acids by our present strategy, and show competitive outcomes in asymmetric reactions. 1 Key Laboratory of Flexible Electronics & Institute of Advanced Materials, Jiangsu National Synergetic Innovation Center for Advanced Materials, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, China. 2 College
    [Show full text]
  • Organic Light-Emitting Diode (OLED) OLED Materials Hole Transport Layer (HTL) / Electron Blocking Layer (EBL)
    Organic Light-EmittingOrganic Light-Emitting DiodeHole Transport(OLED) Layer (HTL) / Diode (OLED) _ OLED Materials Electron Blocking Layer (EBL) Organic Light-Emitting Diode (OLED) _ OLED Materials Hole Transport Layer (HTL) / Electron Blocking Layer (EBL) LT-E101 NPB LT-E105 Spiro-TPD N,N'-Bis(naphthalen-1-yl)-N,N'-bis(phenyl)-benzidine N,N'-Bis(3-methylphenyl)-N,N'-bis(phenyl)-2,7-diamino- CAS No. : 123847-85-8 9,9-spirobifluorene Grade : Sublimed, > 99.5% (HPLC) CAS No. : 1033035-83-4 : Grade : Sublimed, > 99% (HPLC) Organic Light-Emitting Diode (OLED) _ OLED Materials Formula C44H32N2 M.W. : 588.74 g/mole Formula : C51H38N2 UV : 339 nm (in THF) M.W. : 678.86 g/mole PL : 450 nm (in THF) UV : 379 nm (in THF) TGA : > 350 °C (0.5% weight loss) PL : 416 nm (in THF) TGA : > 280 °C (0.5% weight loss) N N N N LT-E102 β-NPB N,N'-Bis(naphthalen-2-yl)-N,N'-bis(phenyl)-benzidine Spiro-NPB CAS No. : 139255-17-7 LT-E106 Grade : Sublimed, > 99% (HPLC) N,N'-Bis(naphthalen-1-yl)-N,N'-bis(phenyl)-2,7-diamino- 9,9-spirobifluorene Formula : C44H32N2 M.W. : 588.74 g/mole CAS No. : 932739-76-9 UV : 349 nm (in THF) Grade : Sublimed, > 99% (HPLC) PL : 416 nm (in THF) Formula : C57H38N2 TGA : > 330 °C (0.5% weight loss) M.W. : 750.93 g/mole UV : 380 nm (in THF) PL : 453 nm (in THF) TGA : > 360 °C (0.5% weight loss) N N N N LT-E103 TPD N,N'-Bis(3-methylphenyl)-N,N'-bis(phenyl)-benzidine CAS No.
    [Show full text]
  • Hydroxydopamine Lesions of the Nucleus Accumbens and the Mglur2/3 Agonist LY379268
    Neuropsychopharmacology (2003) 28, 1440–1447 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Toluene-Induced Locomotor Activity is Blocked by 6- Hydroxydopamine Lesions of the Nucleus Accumbens and the mGluR2/3 Agonist LY379268 1,3 2 ,1 AC Riegel , SF Ali , ED French* 1Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA; 2Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research/US FDA, Jefferson, AR, USA The abuse of volatile inhalants remains a prominent, yet poorly understood, form of substance abuse among youth. Nevertheless, the identification of a mechanism underlying the reinforcing properties of inhalants has been hampered by the lack of a clearly identifiable neural substrate upon which these chemicals act. One ingredient that is common to many abused inhalants is toluene, an organic solvent that is self-administered by nonhuman primates and rodents. Most drugs of abuse have been found to elicit forward locomotion in rats, an effect owing to the activation of mesoaccumbal dopamine (DA) pathways. Thus, the present study was undertaken using two different approaches to determine whether toluene-induced locomotor hyperactivity is also ultimately dependent upon DA neurotransmission in the mesolimbic nucleus accumbens (NAC). Here we report on the effects of 6-hydroxydopamine (6-OHDA) lesions of the NAC or pretreatment with the metabotropic mGlu2/3 receptor agonist LY379268 on toluene-induced locomotor activity. Both procedures, which are known to alter neurotransmission within the NAC, significantly attenuated toluene’s locomotor stimulatory effects. These results provide strong support for a central mechanism of action of inhalants, which in the past has been more typically attributed to general nonspecific mechanisms throughout the brain.
    [Show full text]
  • Pre-Operative Diabetes Medication Management Instructions
    Page 1 of 2 Pre-Operative Diabetes Medication Management Instructions Please follow the instructions listed below unless otherwise instructed by your surgeon Medication Type Day Before Surgery Day of Surgery ORAL ANTIDIABETIC AGENTS Metformin and metformin combination drugs alogliptin/metformin (Kazano) canagliflozin/metformin (Invokamet) dapagliflozin/metformin (Xigduo XR) empagliflozin/metformin (Synjardy) glipizide/metformin (Metaglip) Hold Evening Dose Hold the Dose glyburide/metformin (Glucovance) linagliptin/metformin (Jentadueto) metformin (Glucophage, Riomet) pioglitazone/metformin (Actoplus Met) repaglidine/metformin (PrandiMet, Repaglin) sitagliptin/metformin (Janumet) All other oral agents acarbose (Precose) alogliptin (Nesina) alogliptin/pioglitazone (Oseni) canagliflozin (Invokana) chlorpropamide (Diabinese) colesevelam (Welchol) dapagliflozin (Farxiga) dapagliflozin/saxagliptin (Qtern) empagliflozin (Jardiance) empagliflozin/linagliptin (Glyxambi) glimepiride (Amaryl) glimepiride/pioglitazone (Duetact) No Change Hold the Dose glimepiride/rosiglitazone (Avandaryl) glipizide (Glucotrol) glyburide (DiaBeta, Micronase) linagliptan (Tradjenta) miglitol (Glyset) nateglinide (Starlix) pioglitazone (Actos) repaglinide (Prandin) rosiglitazone (Avandia) saxagliptin (Onglyza) sitagliptin (Januvia) sitagliptin/simvastatin (Juvisync) tolazamide NON-INSULIN INJECTABLE albiglutide (Tanzeum) dulaglutide (Trulicity) exenatide (Byetta, Bydureon) No Change Hold the Dose liraglutide (Victoza, Saxenda) pramlintide (Symlin) Pre-Operative Diabetic
    [Show full text]
  • OSENI (Alogliptin and Pioglitazone) Tablets II May Increase Risk
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS---------------------­ These highlights do not include all the information needed to use • Congestive heart failure: Fluid retention may occur and can OSENI safely and effectively. See full prescribing information for exacerbate or lead to congestive heart failure. Combination use OSENI. with insulin and use in congestive heart failure NYHA Class I and OSENI (alogliptin and pioglitazone) tablets II may increase risk. Monitor patients for signs and symptoms. Initial U.S. Approval: 2013 (5.1) • Acute pancreatitis: There have been postmarketing reports of WARNING: CONGESTIVE HEART FAILURE acute pancreatitis. If pancreatitis is suspected, promptly See full prescribing information for complete boxed warning discontinue OSENI. (5.2) • Thiazolidinediones, including pioglitazone, cause or • Hypersensitivity: There have been postmarketing reports of exacerbate congestive heart failure in some patients. (5.1) serious hypersensitivity reactions in patients treated with alogliptin • After initiation of OSENI and after dose increases, monitor such as anaphylaxis, angioedema and severe cutaneous adverse patients carefully for signs and symptoms of heart failure reactions. In such cases, promptly discontinue OSENI, assess for (e.g., excessive, rapid weight gain, dyspnea and/or other potential causes, institute appropriate monitoring and edema). If heart failure develops, it should be managed treatment and initiate alternative treatment for diabetes. (5.3) according to current standards of care and • Hepatic effects: Postmarketing reports of hepatic failure, discontinuation or dose reduction of pioglitazone in OSENI sometimes fatal. Causality cannot be excluded. If liver injury is must be considered. detected, promptly interrupt OSENI and assess patient for • OSENI is not recommended in patients with symptomatic probable cause, then treat cause if possible, to resolution or heart failure.
    [Show full text]
  • Inhalant Abuse Pediatric Care
    CLINICAL REPORT Guidance for the Clinician in Rendering Inhalant Abuse Pediatric Care Janet F. Williams, MD, Michael Storck, MD, and the Committee on Substance Abuse and Committee on Native American Child Health ABSTRACT Inhalant abuse is the intentional inhalation of a volatile substance for the purpose of achieving an altered mental state. As an important, yet-underrecognized form of substance abuse, inhalant abuse crosses all demographic, ethnic, and socioeco- nomic boundaries, causing significant morbidity and mortality in school-aged and older children. This clinical report reviews key aspects of inhalant abuse, empha- sizes the need for greater awareness, and offers advice regarding the pediatrician’s role in the prevention and management of this substance abuse problem. TYPES OF CHEMICALS AND PRODUCTS ABUSED The term “inhalant” encompasses a wide range of pharmacologically diverse substances that readily vaporize. Most other substances of abuse are classified by grouping together substances that share a specific central nervous system action or perceived psychoactive effect, but inhalant substances that are abused are grouped by having a common route of drug use. Inhalant abuse, sometimes referred to as solvent or volatile substance abuse, can be better understood when the expansive list of inhalants is classified into 3 groups on the basis of what is currently known pharmacologically: group I includes volatile solvents, fuels, and anesthetics; group II includes nitrous oxide; and group III includes volatile alkyl nitrites (Table 1). This classification is also consistent with reported differences in user populations, patterns of abuse, and associated problems seen clinically.1–3 Drugs that do not www.pediatrics.org/cgi/doi/10.1542/ readily vaporize at room temperature, such as cocaine, heroin, nicotine, or alcohol, peds.2007-0470 can also be abused through inhalation, but characteristic pharmacologic properties doi:10.1542/peds.2007-0470 distinguish these substances from inhalants.
    [Show full text]
  • The Effects of the Morphine Analogue Levorphanol on Leukocytes: Metabolic Effects at Rest and During Phagocytosis
    The effects of the morphine analogue levorphanol on leukocytes: Metabolic effects at rest and during phagocytosis Nancy Wurster, … , Penelope Pettis, Sharon Lebow J Clin Invest. 1971;50(5):1091-1099. https://doi.org/10.1172/JCI106580. Studies on bacteria have suggested that morphine-like drugs have effects on the cell membrane. To determine the effect of this class of drugs on a mammalian cell, we selected the rabbit peritoneal exudate granulocyte, which undergoes striking membrane changes during phagocytosis. We examined the effect in vitro of the morphine analogue, levorphanol on phagocytosis and metabolism by granulocytes incubated with and without polystyrene particles or live Escherichia coli. Levorphanol (1 or 2 mmoles/liter) decreased: (a) acylation of lysolecithin or lysophosphatidylethanolamine in the medium (which is stimulated about two-fold during phagocytosis) both at rest (40%) and during phagocytosis (60%); (b) uptake of latex particles and Escherichia coli, as judged by electron microscopy; (c) killing of live Escherichia coli (10-fold); (d) 14 14 + CO2 production from glucose-1- C during phagocytosis by at least 80%; (e) K content of granulocytes (35%); (f) oxidation of linoleate-1-14C by 50%, and its incorporation into triglyceride by more than 80%. However, levorphanol stimulated 2 to 3-fold the incorporation of linoleate-1-14C or palmitate-1-14C into several phospholipids. Glucose uptake, lactate production, and adenosine triphosphate (ATP) content are not affected by the drug. Thus, levorphanol does not appear to exert its effects through generalized metabolic suppression. Removal of levorphanol by twice resuspending the granulocytes completely reverses all inhibition. In line with observations on bacteria, it appears that the complex effects of levorphanol on […] Find the latest version: https://jci.me/106580/pdf The Effects of the Morphine Analogue Levorphanol on Leukocytes METABOLIC EFFECTS AT REST AND DURING PHAGOCYTOSIS NANcY WuRsTE, PETER ELSBACH, ERIc J.
    [Show full text]
  • Consultation Documents
    WHO Drug Information Vol. 29, No. 3, 2015 Consultation documents To receive draft monographs by email please contact Mrs Wendy Bonny ([email protected]), specifying that you wish to be added to the electronic mailing list. The International Pharmacopoeia Carbamazepinum Carbamazepine This is a draft proposal for The International Pharmacopoeia (Working document QAS/15.608, July 2015). The working document with line numbers and tracked changes is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects/en/. Please address any comments to: World Health Organization, Quality Assurance and Safety: Medicines, Dr Herbert Schmidt, 1211 Geneva 27, Switzerland; fax: +41 22 791 4730; email: [email protected]. [Note from the Secretariat. It is proposed to revise the monograph on Carbamazepine in The International Pharmacopoeia.] [Note from the editor. In accordance with WHO editorial policy the text reproduced below does not include tracked changes. Changes from the current monograph are indicated by insert and delete in the working document available at the above-mentioned web address.] Molecular formula. C15H12N2O Relative molecular mass. 236.3 Graphic formula. Chemical name. 5H-Dibenz[b,f]azepine-5-carboxamide; CAS Reg. No. 298-46-4. Description. A white to almost white, crystalline powder. Solubility. Practically insoluble in water; sparingly soluble in acetone; soluble in ethanol (~750 g/L) TS; freely soluble in dichloromethane. Category. Antiepileptic. 352 WHO Drug Information Vol. 29, No. 3, 2015 Consultation documents Additional information. Carbamazepine exhibits polymorphism. The acceptable crystalline form is anhydrous polymorph form III1. It corresponds to carbamazepine RS. Storage. Carbamazepine should be kept in a tightly closed container.
    [Show full text]
  • Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis
    molecules Article Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis Anna Poliwoda * , Katarzyna Zieli ´nskaand Piotr P. Wieczorek Faculty of Chemistry, University of Opole, Oleska 48, 45-042 Opole, Poland * Correspondence: [email protected]; Tel.: +48-77452-7116 Academic Editors: Mihkel Koel and Marek Tobiszewski Received: 20 February 2020; Accepted: 25 March 2020; Published: 29 March 2020 Abstract: The fully automated system of single drop microextraction coupled with capillary electrophoresis (SDME-CE) was developed for in-line preconcentration and determination of muscimol (MUS) and psilocin (PSC) from urine samples. Those two analytes are characteristic active metabolites of Amanita and Psilocybe mushrooms, evoking visual and auditory hallucinations. Study analytes were selectively extracted from the donor phase (urine samples, pH 4) into the organic phase (a drop of octanol layer), and re-extracted to the acidic acceptor (background electrolyte, BGE), consisting of 25 mM phosphate buffer (pH 3). The optimized conditions for the extraction procedure of a 200 µL urine sample allowed us to obtain more than a 170-fold enrichment effect. The calibration curves 1 were linear in the range of 0.05–50 mg L− , with the correlation coefficients from 0.9911 to 0.9992. The limit of detections was determined by spiking blank urine samples with appropriate standards, 1 1 i.e., 0.004 mg L− for PSC and 0.016 mg L− for MUS, respectively. The limits of quantification varied 1 1 from 0.014 mg L− for PSC and 0.045 mg L− for MUS.
    [Show full text]
  • NESINA (Alogliptin) Tablets, for Oral Use • Heart Failure: Consider the Risks and Benefits of NESINA Prior to Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------WARNINGS AND PRECAUTIONS----------------------­ These highlights do not include all the information needed to use • Acute pancreatitis: There have been postmarketing reports of NESINA safely and effectively. See full prescribing information for acute pancreatitis. If pancreatitis is suspected, promptly NESINA. discontinue NESINA. (5.1) NESINA (alogliptin) tablets, for oral use • Heart failure: Consider the risks and benefits of NESINA prior to Initial U.S. Approval: 2013 initiating treatment in patients at risk for heart failure. If heart failure develops, evaluate and manage according to current ---------------------------RECENT MAJOR CHANGES--------------------------­ standards of care and consider discontinuation of NESINA (5.2). Indications and Usage (1.1) 4/2016 • Hypersensitivity: There have been postmarketing reports of Dosage and Administration serious hypersensitivity reactions in patients treated with NESINA Patients with Renal Impairment (2.2) 4/2016 such as anaphylaxis, angioedema and severe cutaneous adverse Warnings and Precautions reactions, including Stevens-Johnson syndrome. In such cases, Pancreatitis (5.1) 4/2016 promptly discontinue NESINA, assess for other potential causes, Heart Failure (5.2) 4/2016 institute appropriate monitoring and treatment and initiate Hepatic Effects (5.4) 4/2016 alternative treatment for diabetes. (5.3) Bullous Pemphigoid (5.7) 12/2016 • Hepatic effects: Postmarketing reports of hepatic failure, ----------------------------INDICATIONS AND USAGE---------------------------­ sometimes fatal. Causality cannot be excluded. If liver injury is NESINA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an detected, promptly interrupt NESINA and assess patient for adjunct to diet and exercise to improve glycemic control in adults with probable cause, then treat cause if possible, to resolution or type 2 diabetes mellitus.
    [Show full text]